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Objective: To test the hypothesis that olfactory (OF) and gustatory function (GF) is
disturbed in patients with autoimmune encephalitides (AE).
Methods: The orthonasal OF was tested in 32 patients with AE and 32 age- and
sex-matched healthy controls (HC) with the standardized Threshold Discrimination
Identification (TDI) score. This validated olfactory testing method yields individual scores
for olfactory threshold (T), odor discrimination (D), and identification (I), along with a
composite TDI score. The GF was determined by the Taste Strip Test (TST).
Results: Overall, 24/32 (75%) of patients with AE, but none of 32 HC (p < 0.001)
had olfactory dysfunction in TDI testing. The results of the threshold, discrimination and
identification subtests were significantly reduced in patients with AE compared to HC
(all p < 0.001). Assessed by TST, 5/19 (26.3%) of patients with AE, but none of 19
HC presented a significant limitation in GF (p < 0.001). The TDI score was correlated
with the subjective estimation of the olfactory capacity on a visual analog scale (VAS;
rs = 0.475, p = 0.008). Neither age, sex, modified Rankin Scale nor disease duration
were associated with the composite TDI score.
Conclusions: This is the first study investigating OF and GF in AE patients. According
to unblinded assessment, patients with AE have a reduced olfactory and gustatory
capacity compared to HC, suggesting that olfactory and gustatory dysfunction are
hitherto unrecognized symptoms in AE. Further studies with larger number of AE patients
would be of interest to verify our results.
Keywords: autoimmune encephalitis, olfactory dysfunction, gustatory dysfunction, olfactory testing, threshold
discrimination identification test
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INTRODUCTION
In recent years, the term autoimmune encephalitis was
established for a heterogeneous group of antibody-associated
disorders of the brain that can either be caused by paraneoplastic
or non-paraneoplastic conditions (1, 2). AE is characterized
by a subacute onset of working memory deficits, psychiatric
symptoms, and altered mental status. According to international
consensus, the diagnosis of definite autoimmune limbic
encephalitis can be made, if the following criteria are met:
MRI abnormalities of the medial temporal lobe, epileptic
slow-waves on EEG, and CSF pleocytosis (3). In anti-NMDA
receptor encephalitis fewer than half of MRIs reveal abnormal
findings (4, 5). Presence of antibodies in CSF and serum
facilitate the diagnosis as well as a positive treatment response
to immunotherapy (6, 7). In 50–60% of AE patients oligoclonal
bands in CSF are detected. Hence, AE is in particular defined by
means of antibodies, which either target intracellular antigens
or surface antigens especially in the limbic system. The existing
diagnostics yield no definitive evidence. So further diagnostic
tests are desirable. Olfactory dysfunction is an increasingly
detected symptom in neuroimmunological disorders such as
multiple sclerosis and neuromyelitis optica spectrum disorder
(8, 9). Essential parts of the olfactory pathway are located in the
limbic system. Olfactory information from the olfactory cortex
(including the piriform and enthorinal cortex, the olfactory
tubercle and the anterior olfactory nucleus) is projected to the
hippocampus, amygdala, nucleus accumbens, and hypothalamus
(10). As the olfactory information is processed in these brain
areas, we hypothesized that functional disturbances of the
limbic system in AE patients could lead to olfactory and
gustatory dysfunction (11, 12). The aim of the study was to
investigate olfactory and gustatory function in AE patients.
Besides possible social, emotional and behavioral consequences
of olfactory, and gustatory dysfunction, its detection using
a standardized test could be a helpful marker of disease
activity (13).
METHODS
Study Participants
In this prospective case-control study, 32 patients with AE (44%
women, 18–75 years, mean ± standard deviation Ø 52 ± 18
years) were examined from April 2015 to May 2016. The median
(±SD) disease duration was 18 ± 13 months. In detail, 26
seropositive (81.3%) and 6 seronegative patients were recruited
at in- and outpatient clinics of the Charité-Universitätsmedizin
Berlin, Germany. Antibody testing was performed in all
patients with seropositive and seronegative AE with the
same commercially available cell-based assay (Euroimmun,
Lübeck, Germany). Six AE patients with anti-leucine-rich
glioma-inactivated 1 (anti-LGI1) antibodies, four with anti-
N-methyl-D-aspartate receptor (anti-NMDAR) antibodies,
four with antiglutamate decarboxylase (anti-GAD) antibodies,
two with anti-contactin-associated protein 2 (anti-Caspr2)
antibodies, two with anti-Hu-antibodies, one with anti-α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
(anti-AMPAR) antibodies, one with anti-γ-aminobutyric
acid B receptor (anti-GABA-B-R) antibodies, one with anti-
voltage-gated calcium channel (anti-VGCC) antibodies, one with
anti-dipeptidyl-peptidase-like protein-6 (anti-DPXX) antibodies,
one with anticollapsin response-mediator protein 5 (anti-CV2)
antibodies, one with anti-metabotropic glutamate receptor
5 (anti-mGluR5) antibodies, and two with not characterized
anti-neuronal antibodies were included in the study. The
diagnosis of AE was verified by two experienced neurologists
according to current peer-reviewed diagnostic criteria (3).
At baseline all patients were already diagnosed and followed
up, none was a de novo patient. Beyond that, none of the
patients have had a herpes simplex encephalitis (HSE) in their
medical history. At the time of testing eight patients received
rituximab for immunotherapy, four patients were treated with
plasmapheresis (between three and ten courses), four with
intravenous immunoglobulins, three with steroids, and one
with bortezomib (7, 14, 15). In addition, four AE patients were
treated with a two-stage treatment. Three of these patients
were first treated with plasmapheresis and afterwards with
rituximab, and one patient was treated with immunoadsorption
and afterwards with rituximab. Overall, 8 out of 32 AE patients
had neither immunosuppressive therapy nor plasmapheresis
at the time of OF and GF testing. The age- and sex-matched
HC group comprised 32 individuals and were recruited among
hospital staff.
Inclusion- and Exclusion Criteria
The patients were included in, respectively, excluded from
the study after ENT and neurological examination as well as
by completing two questionnaires. Patients with the diagnosis
AE were included in the study. Exclusion criteria for study
participants of both groups were known olfactory disorders
(caused by e.g., infections of the upper respiratory tract,
post-traumatic, sinunasal, post-infectious, allergies), a major
depression in medical history, age over 75 as well as
pregnancy and lactation, respectively (16). To exclude olfactory
disorders of sinunasal origin an endoscopic ENT examination
of the nasal passage, the sinuses, and the nasal mucosa
was performed in patients with AE. Furthermore, patients
suffering from diseases associated with olfactory dysfunction
such as Parkinson’s or Alzheimer’s disease, multiple sclerosis
and neuromyelitis optica spectrum disorder as well as patients
taking drugs that can cause olfactory dysfunction (such as
amitryptilin, methotrexat, D-Penicillamine, and certain other
antibiotics, e.g., aminoglycosides, macrolides, and tetracyclines)
were excluded.
The Mini Mental State Examination (MMSE) was performed
before OF and GF testing to exclude severe cognitive dysfunction
(17). AE patients scoring at least 25 out of 30 points were
included. To identify a major depression the Beck Depression
Inventory-II (BDI-II) was applied (18). The BDI-II comprises
21 questions in a self-reported multiple choice form varying in
severity and symptoms of depression such as guilt, hopelessness
and physical symptoms such as fatigue, lack of interest in sex and
weight loss. We predefined a BDI-II score higher as 15 points
as exclusion criterion. Physical disability was rated according
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to the modified Rankin Scale (mRS) score ranging from 0 (no
symptoms) to 6 (death) (19). Patients with a mRS score >3 were
excluded from the study.
Orthonasal Olfactory Function
The orthonasal OF was examined by an unblinded investigator
using the tripartite TDI score (Sniffin’ Sticks test battery;
Burghart GmbH, Wedel, Germany), which is composed of
threshold, discrimination and odor identification subtests and is
recommended by the German Society for Otorhinolaryngology,
Head and Neck Surgery (20). The standardized and reliable
(rtt = 0.72) test is designed as an alternative forced choice (AFC)
test (21). The olfactory perception threshold was determined by a
16-stage dilution series of n-butanol with 48 Sniffin’ Sticks. Using
the AFC principle, blindfolded subjects had to identify the sniffin
stick that contained the odorant. The discrimination test was
performed with 48 Sniffin’ Sticks of different smell qualities to
test the distinction of smells. Everyday odors had to be recognized
with the identification test which consist of 16 Sniffin’ Sticks.
A TDI score of <16 out of 48 indicates functional anosmia,
a score up to 30.5 indicates hyposmia and a score above 30.5
indicates normosmia.
Gustatory Function
To determine the GF, the Taste Strip Test (TST; Burghart GmbH,
Wedel, Germany) was applied (22). The multiple forced-choice
test evaluates the qualities salty, sweet, sour and bitter, each
presented in four different concentrations. A maximum score of
16 points can be achieved. A test score of below nine indicates an
impaired GF.
Secondary Outcomes
To detect confounding factors primary outcomes TDI and
TST scores were tested in a linear regression model with the
mRS-, BDI-, MMSE score, subjective estimation of the olfactory
capacity on visual analog scale (VAS), age, disease duration and
antibody status.
Statistical Analysis
Statistical analysis was performed using SPSS 25.0 (IBM SPSS
Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.).
Figures were created with GraphPad Prism 7.03 (GraphPad
Software Inc., La Jola, USA). The data are presented in
means with standard deviations (SD) (mean ± SD). To test
the normality the Shapiro-Wilk test was performed. Taking
into consideration the non-Gaussian distribution and sample
size, the non-parametric Wilcoxon signed-rank test for paired
data was used to compare TDI and I score of AE patients
with the age- and sex-matched HC. Whereas, the parametric
equivalent Student’s t-test for paired samples was applied to
compare the obtained scores of the TST score as well as
the T and D subtests of AE patients with HC. The AE
patients were categorized into four groups (patients with
antibodies against synaptic receptors, with antibodies against
intracellular antigens, with antibodies against ion channels and
other cell-surface proteins and without antibodies) to analyze
the influence of antibodies on TDI score with the Kruskal-
Wallis H test and on TST score with one-way ANOVA. Finally,
ANCOVA was used to verify the absence of gender influence
on TDI score. Correlations were calculated applying the Pearson
and Spearman correlation. A p-value of <0.05 was defined
as significant.
TABLE 1 | Demographic and clinical data of AE patients and HC.
Characteristics AE patients (n = 32) HC (n = 32)
Gender
Female (%) 14 (44) 14 (44)
Male (%) 18 (56) 18 (56)
Age, mean (SD), y 52.5 (17.8) 52.0 (17.5)
Time after disease onset,
median (IQR), month
19.3 (10.3–25.0) n.a.
Tumors present (%) 4 (12.5) 0
mRS score, mean (SD) 1.7 (1.1) 0
MMSE score, mean (SD) 27.8 (1.7) n.a.
BDI-II score, mean (SD) 8.0 (7.1) n.a.
Acute therapy (%) 15 (47) 0
IV corticosteroids (%) 3 (9) 0
Plasma exchange (%) 8 (25) 0
Immunoglobulins (%) 4 (13) 0
Long-term
immunosuppression (%)
Oral corticosteroids (%)
7 (22) 0
Rituximab (%) 11 (34) 0
Bortezomib (%) 1 (3) 0
Antibodies against
intracellular antigens (%)
7 (22) 0
Hu (%) 2 (6) 0
CV2 (%) 1 (3) 0
GAD (%) 4 (13) 0
Antibodies against synaptic
receptors (%)
7 (22) 0
NMDA receptor (%) 4 (13) 0
AMPA receptor (%) 1 (3) 0
GABAB receptor (%) 1 (3) 0
mGluR5 (%) 1 (3) 0
Antibodies against ion
channels and other
cell-surface proteins (%)
12 (38) 0
LGI1 (%) 6 (19) 0
CASPR2 (%) 2 (6) 0
VGCC (%) 1 (3) 0
DPPX (%) 1 (3) 0
Not characterized (%) 2 (6) 0
Oligoclonal bands (%) 6 (19) 0
AE, autoimmune encephalitis; mRS, modified Rankin Scale score; MMSE, Mini-
Mental State Examination; BDI, Beck Depression Inventory; GAD, glutamic acid
decarboxylase; NMDA, N-Methyl-D-aspartate; AMPA, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid; GABA, gamma-aminobutyric acid; mGluR5, metabotropic
glutamate receptor 5; LGI1, leucine-rich, glioma inactivated 1; CASPR2, contactin
associated protein receptor 2; VGCC, voltage-gated calcium channel; DPPX, dipeptidyl
aminopeptidase-like protein 6; n.a., not available.
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FIGURE 1 | The results of total threshold, discrimination and identification scores (A) and of all olfactory subtests (B–D) in AE patients were compared to HC.
Horizontal bars: mean. AE, autoimmune encephalitis; D, discrimination score; I, identification score; T, threshold score.
RESULTS
The demographics and clinical characteristics of 32 AE patients
and 32 HC examined in this study are presented in Table 1. In
psychophysical TDI testing, a significant olfactory dysfunction
was present in 24/32 (75%) of AE patients, but in none of the
HC (p < 0.001). The GF was significantly limited in 26.3%
(5/19) of AE patients in the TST and none of the HC (p <
0.001). Sixty percent of the patients with a gustatory dysfunction
were also hyposmic, 20% anosmic. The OF results correlated
with the subjective estimation of olfactory capacity on VAS
(r = 0.475, p= 0.008).
Orthonasal Olfactory Function
The overall TDI score in all 32 AE patients was 24.0 ± 9.2,
the 32 HC had a median TDI score of 34.8 ± 2.3 [p < 0.001,
(Figure 1A)]. Effect size for detecting olfactory dysfunction was
r= 0.87. In 53% of all AE patients (17/32) hyposmia was detected
with a score of 25.7 ± 3.3. 7/32 (22%) of AE patients showed
anosmia with a score of 9.1 ± 4.2. All HC showed normosmia
in TDI testing. Moreover, the results of the Threshold subtest
(p < 0.001, Cohen’s d 1.15), the Discrimination subtest (p <
0.001, Cohen’s d 1.39) and the Identification subtest (p < 0.001,
r= 0.85) revealed significant differences between AE patients and
HC (Figures 1B–D). The specificity and the positive predictive
value were 97% with a cut-off score of 13 out of 16 in the
Identification subtest. In addition, the sensitivity was 88% and the
negative predictive value 89%. Comparing TDI scores of female
(25.9 ± 6.7) and male (22.5 ± 10.3) AE patients no significant
difference was found (p= 0.424).
Gustatory Functiozn
The TST score in 19 patients was 11.2 ± 3.4 (Table 2). The
TST score in the 32 HC was 13.5 ± 1.1. 26.3% of the AE
patients (5/19) had reduced GF with a score of 5.8 ± 1.7, while
none of the HC showed gustatory dysfunction. The GF was
significantly reduced in AE patients [p < 0.001, (Figure 2)],
and effect size for detecting gustatory dysfunction was
Cohen’s d = 1.13.
Secondary Outcomes
VAS was used as an instrument for subjective evaluation of OF
and GF. The TDI score correlated significantly with olfactory
capacity expressed on VAS. Besides quantitative self-evaluation
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TABLE 2 | Results of orthonasal and gustatory testing of AE patients and healthy
controls.
AE patients Controls P-value
TDI score, mean (SD) 24.0 (9.2) 34.8 (2.3) <0.001
Hyposmia (%) 17 (53) 0
Hyposmia, mean (SD) 25.7 (3.3) –
Anosmia (%) 7 (22) 0
Anosmia, mean (SD) 9.1 (4.2) –
Threshold, mean (SD) 5.3 (3.2) 7.8 (1.4) <0.001
Discrimination, mean (SD) 9.1 (3.8) 12.3 (1.4) <0.001
Identification, mean (SD) 9.6 (3.8) 14.6 (0.7) <0.001
TST score, mean (SD) 10.2 (3.4) 13.5 (1.1) <0.001
Hypogeusia (%) 5/19 (26) 0/32 (0)
Hypogeusia, mean (SD) 5.8 (1.7) –
AE, autoimmune encephalitis; TDI, threshold discrimination identification test; TST, taste
stripe test.
FIGURE 2 | The TST score in AE patients compared to HC. Horizontal bars:
mean. TST, taste stripe test.
AE patients were also asked for qualitative dysosmia. Two AE
patients reported phantosmia (6.25%), none reported parosmia.
The autoantibody type had no significant influence on TDI score
(Chi-Square = 1.531, p = 0.675, r = 0.41) in the Kruskal-Wallis
H test and in the one-way ANOVA on TST score [F(3, 15) = 0.707,
p = 0.563, η2 = 0.12]. In a linear regression model confounding
factors such as MMSE, mRS, BDI, age, or disease duration had no
influence on OF or GF, respectively.
DISCUSSION
To the best of our knowledge, this is the first study investigating
OF and GF in AE patients. The majority of AE patients, but
none of HC showed olfactory dysfunction. A significant loss
of olfactory capacity in AE patients compared to HC was
seen in all olfactory subtests measuring olfactory threshold,
discrimination, and identification of smells. The threshold
subtest reflects a more peripheral olfactory function, whereas
discrimination and identification depict higher-level processing
of olfactory information (11, 23, 24). The results of the
present single-center study indicate olfactory impairment in
AE patients in peripheral as well as in central olfactory
processing regions.
The primary olfactory cortex such as the piriform cortex,
amygdala, entorhinal cortex, and anterior olfactory nucleus
receive olfactory information from the olfactory bulb and
project them to regions of the secondary olfactory cortex
(e.g., hippocampus, parahippocampal gyrus, insula, inferior
frontal gyrus, and orbitofrontal cortex) (25). Thus, olfactory
impairment in AE patients could arise from functional
disturbances to olfaction-related regions of the limbic system or
from autoantibody-mediated increase and decrease of synaptic
excitation or inhibition (3, 26). Previous neuropathological and
radiological studies revealed a vulnerability of the hippocampus
and amygdala to structural damage in patients with AE (5, 27–
30). In this context, future MRI-studies using specific sequences
such as diffusion tensor imagine (DTI) to detect possible
structural damage of the olfactory pathway and the limbic system
and correlate it with the olfactory capacity of AE patients would
be of interest. Furthermore, it would be interesting to measure
olfactory bulb (OB) and olfactory brain volumes of AE patients
as these parameters seem to reflect well the olfactory capacity
(31, 32). Acute inflammation in olfaction related regions of the
limbic system could possibly lead to reduced olfactory bulb
and olfactory brain volumes. The capability of neurogenesis in
the subgranular zone of the hippocampus and subventricular
zone of the lateral ventriceles was investigated in former
studies (33–35). The migration of neuroblasts along the rostral
migration stream to the OB leads to a high placticity of the
OB. Thus, OF in AE patients could possibly improve after
immunomodulatory treatment in the course of disease due to
regeneration of OB.
The loss of peripheral olfactory function as well as of
central olfactory function detected in our study might be
explained by the cortical olfactory feedback system (35, 36).
Aqrabawi et al. (37) identified the ventral hippocampus as a
limbic input in a top-down modulation of olfactory sensitivity
via pars medialis of the anterior olfactory nucleus to the
olfactory bulb.
Olfactory dysfunction is not specific for AE patients.
However, the association of olfactory dysfunction with
neuroimmunological diseases was shown in different studies
(38). In a recent MRI study the OF of multiple sclerosis and
neuromyelitis optica spectrum disorder was compared (39).
It was shown that the neuroanatomical features related to
olfactory deficits differ between the two diseases, i.e., the
same symptom is based on different pathomechanisms. To
distinguish OF in AE patients from other neuroimmunological
diseases further MRI studies comparing olfaction related
brain regions of different disease entities would be of interest.
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In a recent prospective study, Armangue et al. (40) showed
that 27% of HSE patients develop AE. In our study none of
the 32 AE patients had a HSE in their medical history. An
immunohistological study showed that HSV was present in the
olfactory cortex and in glia cells of olfactory tracts (41). OF in
HSE patients was hitherto not examined. In this context, it would
be of interest to examine OF in HSE and to compare it with
AE patients.
In detail, 26% of AE patients showed hypogeusia in gustatory
testing and 80% of these patients also displayed olfactory
impairment. Intersections between the olfactory and gustatory
system on a cortical level might explain the high incidence of
combined OD and GD due to damage in regions of the central
nervous system like the amygdala, the orbitofrontal cortex, the
thalamus or the insula (42–44).
In our study the OF and GF of AE patients was neither
correlated with the presence or categorization of antibodies nor
the disease durationmost likely due to the small sample size of the
subgroups. To analyze the impact of antibody status and antibody
titer on OF and GF, four groups (antibodies against synaptic
receptors, against intracellular antigens, against ion channels and
other cell-surface proteins and without antibodies) ranging from
6 to 12 patients were formed (3).
A limitation of our study is the single-center design and
a heterogeneous and small sample with few patients in the
different antibody subgroups, related to the rarity of AE (45).
Further studies with a larger number of patients with different
AE syndromes are required to detect possible differences between
different AE subgroups. That might further explain different
pathomechanisms leading to olfactory and gustatory impairment
in AE patients. Another limitation of our study is that patients
with severe cognitive deficits and high physical disability in
particular at an intensive care unit setting had to be excluded
in order to participate at the different tests (46). Especially
these patients might show increased structural damage to the
limbic system possibly leading to more severe damage of the
olfactory pathway. Thus, OF and GF might be even more
severely impaired in AE patients than reflected in our results.
Moreover, it is a limitation of our study that the effect of
different immunomodulatory treatments on OF and GF was not
examined. It would be interesting to investigate in a longitudinal
study whether the severity of olfactory and gustatory dysfunction
is depending on the immunomodulatory therapy.
In summary, this is the first study investigating olfactory
and gustatory function in AE patients. We conclude that
olfactory and gustatory dysfunction are hitherto uncharacterized
symptoms in AE patients, similar to visual dysfunction in
patients with NMDA receptor encephalitis (47). We suggest
performing further studies with a larger number of patients. The
Identification subtest could be used as an olfactory screening
test in clinical routine in patients with suspected AE, as it is
easy to perform, time and cost effective, and showed a high
sensitivity and specificity to differentiate betweenAE patients and
HC. It would be interesting to investigate in a longitudinal study
whether changes in olfactory capacity might reflect treatment
response to immunomodulatory therapy. Furthermore, the AE
patients in our study were tested in average 19 months after
disease onset. Both the examination of OF and GF in AE
patients with acute disease onset and the longitudinal follow
up testing are needed to evaluate the potential diagnostic
and prognostic role of olfactory and gustatory testing in AE
patients. In addition, our findings might contribute to a better
understanding of disease pathomechanisms. Inflammation in
olfactory and gustatory structures caused by autoantibodies in
AE patients could explain the presence of olfactory and gustatory
disturbances in these patients.
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